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Abstract There is considerable evidence that prescribed
drugs are not taken as intended. We present a stochastic
pharmacokinetic mathematical model that can be used to
assess the implications of non-adherence to prescribed drug
regimens, on the part of either patients or health professio-
nals. In the context of an orally administered drug, explicit
equations are derived for the time varying mean and variance
of the concentration of the drug in the serum, depending on
the probability of each scheduled administration being
omitted. The analysis presented here can be used to assess
whether a given level of non-adherence is likely to have a
clinical impact. The methods used can easily be adapted for
use in the context of other routes of drug administration.
Keywords Pharmacy . Pharmacokinetics . Non-adherence .
Mathematical modelling . Stochastic analysis .
Compartmental models
1 Introduction
For medicines to work as intended, they should be taken as
prescribed, yet there is considerable evidence that this
frequently does not happen. In-hospital studies have shown
that drug administration errors are relatively common, with
3–8% of non-intravenous drug administrations involving at
least one error, omission of the administration accounting
for roughly half of this figure [1–8].
Outside hospital, non-adherence is also a major problem.
Many studies [9–11] have shown that frequently patients do
not take their medicine as intended. Adherence to a drug
regimen is particularly poor for those with chronic
conditions [11], with only around 50% of patients taking
their medicine as prescribed [10]. The adverse effects of not
taking medicine as prescribed have been observed in
empirical studies [12–14]. Within this literature, the focus
tends to be on the important question of quantifying patient
adherence.
To date, little attention has been paid to the question of
modelling the harm associated with non-adherence (either
on the part of the patient or due to an error by a health care
professional in the prescribing, dispensing or administration
of the drug). In this paper, we discuss mathematical
modelling methods that can be used to explore this in
terms of consequent pharmacokinetic effects. Others have
investigated the same topic using computer simulation [15,
16]. However, the analysis presented here is purely
mathematical, showing that in some circumstances it is
possible to derive explicit stochastic pharmacokinetic
formulae for the time varying mean and variance of the
serum concentration of a prescribed drug.
Our analysis gives a powerful extension to existing
pharmacokinetic theory and, while discussed here in the
context of a simple first order absorption and elimination
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system, it has much wider applicability. One use of our
analysis which we discuss concerns assessing how non-
adherence can disrupt one of the main clinical aims of drug
therapy, that of achieving drug concentrations that fall
within a given therapeutic range.
2 An elementary pharmacokinetic model
Pharmacokinetics is one of the most common uses of
mathematical modelling within health care. Compartmental
models are used to describe the absorption, transport and
elimination of an administered drug by the body. A
simplistic view of such models is that each compartment
represents a physiological entity within the body, such as
the gut or the serum. In practice pharmacokinetic modelling
can be more general, compartments often not being
explicitly identified with physical subsystems of the body.
However in this paper we adopt the former view, extension
to the more general case being straightforward. The
quantities of drug present in each compartment are
modelled as being governed by a set of differential
equations, solutions to which can be used to derive time-
varying expressions for the quantity of drug present, given
a specific drug regimen. Such analysis will be illustrated
with a simple pharmacokinetic model reflecting the effects
of oral administration of a drug (see Fig. 1).
We first introduce notation, denoting the quantity of drug
in the gut at time t by Q1(t) and the quantity of drug in the
serum by Q2(t). We assume that the serum has an apparent
volume of distribution of V, thus the concentration of the
drug in the serum is Q2(t)/V. The rate parameters α1 and α2
respectively reflect the rate of transfer of the drug from the
gut to the serum and the rate of elimination of the drug
from the serum. In this example they are assumed to have
different values.
We assume that drug absorption and elimination are first
order processes, such that Q1(t) and Q2(t) are governed by
the following system of differential equations:
dQ1 tð Þ
dt
¼ a1Q1 tð Þ ð1Þ
dQ2 tð Þ
dt
¼ a1Q1 tð Þ  a2Q2 tð Þ ð2Þ
If the drug is not administered between time t0 and some
later time t0+τ then solutions to Eqs. 1 and 2 are given by:
Q1 t0 þ tð Þ ¼ Q1 t0ð Þea1t ; ð3Þ
and
Q2 t0 þ tð Þ ¼ a1a2  a1ð Þ e
a1t  ea2tð ÞQ1 t0ð Þ
þ Q2 t0ð Þea2t : ð4Þ
3 Modelling the effects of a sequence of drug
administrations
We now consider a sequence of oral drug administrations.
As is standard within pharmacokinetics, the effects of such
a regimen is modelled by assuming that Q1(t), the quantity
of drug in the gut, increases instantaneously by the size of
each dose administered at the scheduled time for adminis-
tration (for instance see [18]). This implicitly assumes that
an administered drug is completely absorbed, however the
adjustment to the analysis required to take account of
incomplete absorption is mathematically trivial.
Introducing additional notation, suppose that there is a
schedule of drug administrations of doses {d0, d1,…} to be
given at times {t0, t1,…}. For 0≤k, let the contribution of
the k-th drug administration to the quantity of drug in the
gut at time t be denoted by q1,k(t) and to the quantity in the
serum be denoted by q2,k(t). In view of Eqs. 3 and 4, these
are given by
q1;k tð Þ ¼ H t  tkð Þdkea1 ttkð Þ ð5Þ
and
q2;k tð Þ ¼ a1H t  tkð Þa2  a1ð Þ dk e
a1 ttkð Þ  ea2 ttkð Þ
 
ð6Þ
where H(x) is a step function defined by
H xð Þ ¼ 1; for x  0;H xð Þ ¼ 0; for x < 0: ð7Þ
Use of this step function means that formulae 5 and 6
apply for all values of t, including those before tk, the k-th
time in the sequence {t0, t1,…}.
Given the linear nature of the differential Eqs. 1 and 2
and assuming that no drug is present in either the gut or the
serum prior to the first scheduled administration, the
Fig. 1 The compartmental representation of the pharmacokinetic
process associated with oral administration of a drug
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quantity of drug in each compartment at time t is the sum of
the individual contributions to that compartment from each
drug administration. Thus we have
Q1 tð Þ ¼
X
k¼0
q1;k tð Þ ¼
X
k¼0
H t  tkð Þdkea1 ttkð Þ ð8Þ
and
Q2 tð Þ ¼
X
k¼0
q2;k tð Þ ¼ α1α2  α1ð Þ
X
k¼0
H t  tkð Þdk 




The serum drug concentration at time t can be derived by
dividing Eq. 9 by V, the volume of distribution.
4 A stochastic pharmacokinetic model for a scheduled
sequence of drug administrations when omission
probabilities are independent
We now explore the effect of non-adherence on the serum
drug concentration, noting that this non-adherence can be
caused either by the patient failing to take medicines, or by
a health care practitioner failing to administer medicine in a
hospital or care centre.
Up to this point in the analysis it has been implicit that
dk, the quantity of drug given at the k-th administration, is a
deterministic quantity. The key step in our analysis is to
revise this assumption and to treat the set of quantities {dk}
as independent random variables with expectations {E[dk]}
and variances {Var[dk]} respectively.
Under this revised assumption, at any given time t, the
quantities {q2,k(t)} are also random variables. However Eq. 9
holds since each term in the series satisfies the differential
Eqs. 1 and 2 whether {dk} are random or non-random
variables.
Recall that for a set of independent random variables









E akxk½  ¼
X
k¼0










Var akxk½  ¼
X
k¼0
a2kVar xk½ : ð11Þ
Applying Eqs. 10 and 11 to 9, the quantity of drug in the
serum at time t has an expectation and variance given by:
E Q2 tð Þ½  ¼
P
k¼0
E q2;k tð Þ
 
¼ α1
α2  α1ð Þ
X
k¼0
H t  tkð Þ 





Var Q2 tð Þ½  ¼
P
k¼0
Var q2;k tð Þ
 
¼ α1
α2  α1ð Þ
 2X
k¼0
H t  tkð Þ 




H(x) being the step function defined in Eq. 7.
We highlight these equations since they are the key
finding in the paper. It should be noted that these results are
very general. There are no restrictive assumptions about
times at which drug administrations are scheduled and these
do not have to be equally spaced. Mathematically, the
sequence does not need to be assumed finite.
The nature of the random variables {d0, d1,…}
corresponding to the drug doses taken at times {t0, t1,…}
are also very general. Although they are assumed indepen-
dent, there are no other implicit assumptions about how
they are distributed, other than that the means and variances
are defined.
The expressions given in Eqs. 12 and 13 provide a
means of calculating the mean and variance of the quantity
of drug in the serum, and hence the serum concentration, in
a context where the doses of drug received by a patient are
not certain. Equivalent results can be obtained pertaining to
any additive pharmacokinetic model.
5 A specific case study using the general model
It is useful to illustrate the potential use of the general
results summarised in Eqs. 12 and 13 by considering a
specific case study (although there are many other scenarios
that could be investigated).
5.1 Non-adherence to a regimen of regular drug
administrations of equal dose
Here we consider the analysis of a scenario where the
intended dose for each scheduled administration is D and
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the time interval between each potential administration is I.
To model non-adherence we assume that at each scheduled
administration there is a fixed probability p that the patient
fails to take the drug. We also assume that the patient only
takes the drug, if at all, at the scheduled times.
In this context, using standard results from probability
theory, the expectation and variance of the amount of
drug received at the k-th scheduled administration are
given by
E dk½  ¼ D 1 pð Þ; ð14Þ
and
Var dk½  ¼ D2p 1 pð Þ: ð15Þ
Setting t0=0 gives tk=kI, for k≥0.
Substituting Eq. 14 into Eq. 12 and Eq. 15 into Eq. 13
gives the following expressions for the expected value and
the variance of the serum drug concentration at time t
following initiation of treatment, denoted by μ(t) and σ2(t)
respectively:
μ tð Þ ¼ Dα1 1 pð Þ
V α2  α1ð Þ X
k¼0
H t  kIð Þ eα1 tkIð Þ  eα2 tkIð Þ
  ð16Þ
and
σ2 tð Þ ¼ Dα1
α2  α1ð ÞV
 2
p 1 pð Þ 
X
k¼0




For a given t, these expressions simplify, since there are
only a finite number of potential drug administrations that
could have occurred by that time. Also, by mathematical
good fortune, the series in Eqs. 16 and 17 are geometric
progressions and thus re-expressible without summation.
Hence, for n≥0 and 0≤τ<I,
μ nI þ τð Þ ¼ Dα1 1 pð Þ
V α2  α1ð Þ 
eα1τ
1 eα1 nþ1ð ÞI
1 eα1I
 






σ2 nI þ τð Þ ¼ Dα1V α2α1ð Þ
 2





þ e2α2τ 1e2α2 nþ1ð ÞI1e2α2 I
 h




While seemingly complex, these equations are easily
evaluated.
5.2 The steady state case in the scenario of equal durations
between scheduled drug administrations
This specific example of the application of the general
formulae 12 and 13 can be extended.
In the context of the management of a patient with
chronic disease where it is intended that a patient follows a
specified drug regimen over a long period of time, the meanbm tð Þ and variance bs2 tð Þ of the steady state drug concen-
tration a time τ after a scheduled drug administration can be




τð Þ ¼ Dα1 1 pð Þ










2 τð Þ ¼ Dα1
V α2  α1ð Þ
 2










Having obtained these analytical expressions for the mean
and variance of drug concentration at steady state, it is
possible to assess the effect of non-adherence on patient care.
From the form of Eq. 6, it can be seen that the random
variables {q2,k(t)} are not equally distributed. Indeed one
may expect that the potential contribution to the serum
concentration associated with a recent scheduled administra-
tion to be much larger than the potential contribution from a
scheduled administration some time ago. In view of this,
serum drug concentration at a given point in time cannot be
expected to be normally distributed. That said, comparing
the mean and standard deviation of the drug concentration to
the limits of the therapeutic range provides a strong
indication of whether variability in drug concentration due
to non-adherence is a cause for clinical concern.
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5.3 Numerical consequences in the scenario of equal
durations between scheduled drug administrations
The drug mexiletene is used to treat ventricular arrhyth-
mias, especially after myocardial infarction [17]. It can be
taken for several months to help prevent arrhythmia, and
generally has to be taken three times a day to keep the
serum concentration roughly constant. Since arrhythmia is a
dangerous condition, patient adherence while taking mex-
iletene is especially important. The pharmacokinetics of
mexiletene can be described by Eqs. 1 and 2 using
parameter values available from the literature [18].
Figure 2a and b show the expected serum concentration
versus time for the first eight scheduled drug administra-
tions and then the steady state concentrations in the cases
where the probability of omitting a scheduled administra-
tion is 0.1 and 0.4 respectively. In each case, the bold
horizontal line represents the lower limit of the therapeutic
range as given in [18].
The probability distribution of the serum drug concen-
tration is not Gaussian and using the calculated standard
deviation to estimate prediction intervals under the assump-
tion of normality would be misleading. Nonetheless, the
standard deviation can give a broad idea of the likely
clinical impact of a particular degree of patient non-
adherence. If the mean concentration is within the thera-
peutic range and the standard deviation is only a small
fraction of the differences between the mean concentration
and each limit of the therapeutic range, then that level of
patient non-adherence is probably not a major problem
(Fig. 2a). On the other hand, if the standard deviation is the
same order of magnitude as the difference between the
mean concentration and either limit of the therapeutic
range, clearly there would be cause for concern (Fig. 2b).
It would be preferable to have the exact estimates for the
probability that a patient with a chronic condition and with
a given adherence rate would have a serum drug concen-
tration below the therapeutic range. We have developed an
algorithmic method for doing so [19] but giving details of
this is beyond the scope of the present paper and is not in
keeping with the present theoretical extension of pharma-
cokinetic theory.
6 Discussion
We have extended deterministic pharmacokinetic modelling
to include stochastic features related to the probability that
a planned drug administration actually happens. The
analysis has considerable generality. For example, both
the size of dose and the probability of correct administra-
tion may vary for each scheduled administration. Also, our
analysis is suitable for assessing both non-adherence on the
part of patients and non-adherence to protocol by health
care professionals.
The case of a simple absorption and elimination process
has been used to illustrate such analysis. In the case where
there is a fixed probability of missing a particular drug
administration, we have derived explicit formulae for time-
varying mean and variance of drug concentrations depend-
ing on the drug regimes intended and the rates of
adherence, assuming non-adherence errors to be indepen-
dent of one another.
The approach presented here can be applied to other
pharmacokinetic models and hence to a wide range of
medicines. In the case of a pharmacokinetic model with
more compartments, the relevant equations for the mean
and variance of the serum concentration look more complex
but are no less tractable. There is also scope for modelling
more complex drug regimens involving several drugs
Fig. 2 a The serum concentration of mexiletine versus time if the
probability of omitting each scheduled dose is 0.1. The horizontal line
indicates the lower limit of the therapeutic range. b The serum
concentration of mexiletine vs time if the probability of omitting a
scheduled dose is 0.4. The horizontal line indicates the lower limit of
the therapeutic range
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allowing for the possibility that, not only might an
administration be missed, but that the wrong drug might
be taken. The assumption of the independence of non-
adherence errors greatly simplifies our analysis, but
alternative models of adherence might also be amenable
to similar methods.
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